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Summary.-Concentrations of 5-fluorouracil (FU) were measured in the plasma of
patients receiving i.v. infusions of the drug for 5 days as treatment for adenocar-
cinoma of the gastrointestinal tract. Concentrations of FU varied widely in many
patients. Concentration of drug x time of infusion (C x t values) were calculated.
Patients showing a partial response or stabilization of disease had significantly
higher C x t values than non-responders. Methyl CCNU did not affect the C x t
values of FU. Determination of the plasma concentration of FU would allow the dose
of the drug to be adjusted to maintain high concentrations of FU in the plasma. Our
data suggest that such high concentrations would increase the response rate in this
disease.
THE RESPONSE ofadenocarcinoma ofthe
gastrointestinal tract to treatment with
FU is less when the drug is given orally
than i.v. (Hahn et al., 1975). Also, the
various regimens used for i.v. treatment
produce different response rates (Ans-
field et al., 1977). Of these regimens,
continuous infusion of drug for 5 days is
the least toxic (Seifert et al., 1975) and,
when combined with other drugs, gives
good clinical responses (Woolley et al.,
1976). Some data are available on the
plasma concentrations of FU after i.v.
injection or oral administration (Cohen
et al., 1974), but only one other published
study (Clarkson et al., 1964) besides our
preliminary report (Kawai et al., 1977)
gives data on plasma concentrations of
drug during continuous i.v. infusion.
These concentrations varied widely in the
same patient during infusion, and the
values of drug concentration x time
varied widely between different patients.
The present study was carried out to
determine whether these drug concentra-
tions related to tumour response and
whether the administration of methyl
CCNU on Day 1 of the infusion altered
the plasma concentrations of FU.
MATERIALS AND METHODS
Selectionofpatientsand treatmentschedule.-
Patients with measurable metastatic adeno-
carcinoma of the gastrointestinal tract who
had not received FU or methyl CCNTU
previously were treated by i.v. infusion of
FU, 1-2 g/m2/day (not > 2 g) in 1 1 of 5%
dextrose for 5 days. Infusion was either by
gravity or with a Holter pump, on a non-
random basis. Infusions were routinely
supervised in a general medical ward. Some
patients received methyl CCNU 150 mg/M2
by mouth on Day 1. Treatments were
repeated at intervals of 6 weeks, unless
severe drug toxicity or progression of disease
occurred. Plasma levels of FU were deter-
mined during one or more of these courses.
Evaluation of toxicity and tumour response.
-Stomatitis was graded as 1 if present but
Address for reprints: Dr Brian L. Hillcoat, Laboratory of Medicinal Chemistry and Biology, Develop-
mental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Mary-
land 20014.B. L. HILLCOAT ET AL.
not affecting food intake, 2 if preventing
intake of solid but not soft and liquid food,
and 3 if preventing intake of anything by
mouth. Haematological toxicity was not
evaluated, as the patients were discharged
from hospital at the time a fall in white cells
and platelets would have occurred. More-
over, this form of toxicity is infrequent and
asymptomatic when FU is given by continu-
ous infusion at the dosage used (Seifert et al.,
1975).
A complete response was defined as the
disappearance of all disease; partial response
was the objective response as described by
Seifert et al. (1975); stabilization of disease
was defined as no increase in the size of
measurable lesions and no appearance of new
lesions and no deterioration in laboratory
tests over a period of 60 days, or cases which
did not fulfil the requirements for a partial
response; progression of disease occurred if
there was objective evidence of progression,
seen as an increase in the size of metastatic
lesions or the appearance of new lesions or
increasingly abnormal values in laboratory
tests.
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Determination ofplasma levels ofFU.-Five
ml of blood wvas taken from Patients 5, 6, 10
and 11 from 8 to 11 times, at varying inter-
vals as showin in Table I. For the other
patients, blood samples were removed at
daily intervals. The blood removed by
venepuncture was collected in EDTA and the
plasma removed and frozen. Batches of
plasma were thawed and extracted as
described and the FU deterImined by a mass-
spectrometric method, previously reported.
The standard error of our method with
repeated analyses on the same sample was
± 4% and the sensitivity 5 ng/ml (Hillcoat
et al., 1976).
RESULTS
Plasma concentrations of 5-fluorouracil
varied considerably between patients and
in the same patient during infusion.
Typical data are shown in Fig. 1, in
which one patient (3) showed low levels
of drug and wide variation (10-fold) and
another patient (25) high levels of drug
and little variation (2-fold). Tables I and
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FIG. 1. Variations in the plasma levels of 5-fluorouracil in two patients during treatment by
5-day infusion of the drug. O~ 0, Patient 3; * *, Patient 25, (Table III).
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TABLE I. Plasma concentrations of 5-fluorouracil (ng/ml FU) during 5-day infusions
by gravity
Group A:
Patient
5(a) Time (h)
Level
5(b) Time (h)
Level
6 Time (h)
Level
10 Time (h)
Level
11 Time (h)
Level
8
200
8
94
1
16
2
157
30
Group B:
Patient
2
3
4
7
8
9(b)
12
14
16
18
19
20
21
22
24(a)
(b)
25
27
13
28
25
20
17
5
20
<5
16
66
:32 56 63 80 87
80 85 108 43 158
42 49 66 73 90
44 42 214 150 28
24 41 48 72 89
36 59 5 88 99
26 44 50 68 74
42 <5 <5 :35 328
23 40 47 64 71
88 112 93 49 23
104
82
120
68
93
95
92
53
88
494
Day
_ A~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
44
46
56
100
180
192
64
_ 2
250
258
172
246
191
384
171
342
440
180
2
45
21
55
46
140
106
270
370
2
400
150
162
248
282
215
361
415
536
3
54
125
148
104
100
72
61
470
70
42
155
349
134
169
166
887
344
1 i-atio of maximnum to minimum concentratioin.
2 Inot done.
3 i-epeated on same sample.
4
50
13
36
303
60
106
65
83
370
100
583
106
517
369
748
143
971
22163
20003
5
58
46
34
132
130
<5
127
53
210
467
185
559
224
170
284
365
354
180
II give the drug levels for patients treated
bygravity and pump infusion respectively.
C x t values were calculated from the
area under curves such as those in Fig. 1.
These values are shown in Table III.
Patients 5, 9 and 24 had 2 infusions each,
and the average of these values was used
for statistical analyses. For a distribution
plot, C x t values were grouped in ranges
of 5 units: 0-5, 5-10 etc. Fig. 2 is a
distribution of C x t values. For all
27 patients (Table III), the mean C x t
value was 24-2 units (mg h FU/ml), the
median, 15*9 ui and the mode (Fig. 2),
10-15 u. Patients showing toxicity to FU
had a mean C x t value of 193 u and a
median value of 14-5 u; non-toxic patients
had a mean of 27-6 u and a median value
of 17 7 u. Patients showing a partial
response or stabilization of disease had
mean values of 36*1 u and a median value
of 29*9 u, and non-responders a mean of
19-2 u and a median of 15*8 u. Inspection
of the data (Fig. 2) also indicates that
responding patients (PR and S) had higher
C x t values than non-responding
patients (NR), while toxic patients (Ti,
T2, T3) did not have high C x t values.
Statistical analysis was carried out by
not assuming a normal distribution of
values, since Fig. 2 shows skewing on the
right. Wilcoxon's rank-sum test (Dixon &
Massey, 1969) was therefore used and
gave a probability of 0 05 (2-tailed) that
the difference between responders and
non-responders occurred by chance. The
Rangel
7-fold
11-fold
Ill
133
113
119
98
136
112
81
117
54
116
403
24-fold
122
120 81-fold
21-fold
Rangel
Constant
10-fold
4-fold
7-fold
3-fold
38-fold
4-fold
9-fold
5-fold
11-fold
4-fold
5-fold
4-fold
2-fold
5-fold
6-fold
2-fold
12-fold
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TABLE II.-Plasma concentrations of
FU(ng/ml) during 5-day infusion by
pump
Day
A_
Patient 1 2 3 4 5 Range'
1 40 49 40 16 9 5-fold
9(a) 108 <5 182 100 264 53-fold
13 218 115 92 115 204 2-fold
15 134 134 128 228 332 2-fold
17 172 144 314 230 295 2-fold
23 230 216 144 320 1128 8-fold
26 385 528 725 428 392 2-fold
1 ratio of maximum to minimum concentration.
difference in the C x t values of toxic
and non-toxic patients and of those
receiving either FU alone or FU with
MeCCNU were not significant.
DISCUSSION
The drug 5-fluorouracil remains the
most effective single agent in chemo-
therapy of adenocarinoma of the gastro-
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intestinal tract, and is used in combina-
tion chemotherapy for this disease. Never-
theless, we do not know the best method
and schedule of administration. Some
studies indicate that an i.v. loading dose of
FU gives the best response (Ansfield et al.,
1977) while others suggest that i.v.
infusion for 5 days with or without other
drugs increases the frequency of response
and may increase survival (Grillo-Lopez
etat., 1977; Buroker etal., 1977). Objective
responses obtained by the Eastern Co-
operative Oncology Group were 6% at a
dose of 7-5 mg/kg, 20% at 15 mg/kg and
25% at 20 mg/kg (Horton et al., 1970).
Increasing the dose of FU during a 24h
infusion, repeated in 1 or 2 weeks, allows
high doses of drug (up to 16 g/24 h
infusion) to be given with regression and
stasis of large refractory tumours (Spiers
et al., 1977). This dependence of response
on dose suggests that response may
correlate with the plasma concentration
of the drug, in spite of the complex bio-
TABLE III.-C x t values ofFU (mg/h/ml), patient response and drug toxicity
Infusion
Patient C x t Response2 Toxicity pump MeCCNU
1 3-0 NR 2 + -
2 5-4 NR 0 - +
3 5-6 NR 3 - -
4 7-8 NR 0 - +
5 10-6, 8-4 (9-5)1 NR 0 - -
6 10-2 NR 0 - -
7 12-6 NR 3 - -
8 13-6 NR 3 - +
9 11-6,16-7 (14-2)1 NR 0 + -
10 14-3 S 2 - -
11 14-5 S 1 -
12 15-6 S 0 - -
13 15-8 NR 0 + -
14 15-9 NR 0 - -
15 23-4 NR 3 + -
16 23-5 NR 0 - +
17 24-6 NR 3 + +
18 28-1 NR 0 - -
19 29-2 PR 3 - -
20 29 -6 NR 0 - -
21 30-6 S 1 - -
22 32-4 NR 0 - -
23 38-9 NR 0 + -
24 36-5,45-3 (41)1 S 1 - +
25 51-2 NR 0 - -
26 55-2 S 0 + -
27 88-4 PR 0 - -
1 average of 2 infusions.
2 NR, no response; S, stabilization; PR, partial response.NR
NR
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FIG. 2. Distribution of C x t values ofeach of 27 patients. NR, non-responder; 5, stabilized disease; PR, partial responder; TI, T2, T3, increasing levels ofdrug toxicity. The C x t values were calcula- ted as areas under curves such as those in Fig. 1.
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chemical and kinetic steps involved in
the ultimate action of FU on the tumour
cell. In a similar way, high plasma con-
centrations of methotrexate after large
doses of the drug produce responses in
tumours resistant to lower plasma con-
centrations. Plasma levels of FU are also
important when the drug is given with
thymidine. Phase I studies have then
shown marked elevation and prolongation
of FU levels in the plasma, with increased
marrow toxicity compared to FU alone
(Vogel et al., 1978). The enhanced tumour
effect reported in animals given this
combination (Martin et al., 1978) may
result from the high level of FU main-
tained over a considerable period of time.
However, the action of the drug under
these conditions may be qualitatively
different from that when the drug is
given alone (Nayak et al., 1978).
Our results indicate a positive correla-
tion between plasma levels of drug and
tumour response. Gudauskas and Goldie
(1978) have recently presented data show-
ing a similar correlation and confirming
the variability we observe. Since FU given
as an infusion is less toxic to the marrow
than when given as a single i.v. injection
(Seifert et al., 1975) successive treatments
by infusion could use increasing doses
as needed to maintain a level of drug at
or above 36-1 C X t units, the mean value
for responders in our series.
Methyl CCNU did not alter plasma
concentrations of FU, so the reported
synergism of this agent with FU (Moertel
et al., 1975) is not due to changed plasma
concentrations of the latter drug.
Plasma concentrations of FU fluctuated
more widely with gravity infusion than
with pump infusion, as expected. These
concentrations reflect the short half-life
(an a, phase of 12 min) of the drug in the
plasma (Kirkwood & Frei, 1978).
Our data indicate that an increased
rate of response may result if the plasma
concentration of FU were used to adjust
the dose of drug administered. Combined
with the method of predicting marrow
toxicity which we reported previously
(Hillcoat et al., 1977) this approach may
allow an optimum and individualized
use of FU.
This work was supported by IBM (Canada). Grateful acknowledgement is made to the daughter,
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